drugset / Trial / NCT05690932

A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers

NCT05690932

Phase 1 Completed 33 enrolled Pyramid Biosciences
RandomizedCrossoverOpen-labelTreatment

Summary

This is a single-dose, two-part, crossover formulation bridging and food effect study to assess the effect of formulation and food on the absorption and bioavailability of PBI-200 in normal, healthy volunteers.

Timeline

Start
2022-02-24
Primary completion
2022-05-23
Completion
2022-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject PALTIMATRECTINIB Small molecule

Indications

No indication recorded.